Please assess the completion status of the following clinical trial:

Trial Title: Effect of Celecoxib on Perioperative Inflammatory Response in Colon Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- Colon cancer patients with no evidence of metastasis in distant organs (i.e., TNM stage I-III), who are~* between 18 and 75 years old,~* have a body mass index (BMI) between 18 and 35 kg/m\^2,~* and are eligible for laparoscopically-assisted colectomy for primary tumor resection.~* Patients must have the ability to understand and the willingness to sign a written informed consent document.~Exclusion Criteria:~- A history of allergic-type reactions to celecoxib or sulphonamides,~* a history of asthma, skin reactions or other allergic reactions to aspirin or other NSAIDs,~* a history of thromboembolic event (cerebrovascular accident, transient ischemic attack,~* unstable angina, myocardial infarction, deep vein thrombosis, or pulmonary embolism),~* renal insufficiency (defined by a serum creatinine level \> 1.5 mg/dL or blood urea nitrogen level \> 22 mg/dL),~* active gastrointestinal bleeding in the 60 days before surgery,~* alcohol or drug abuse, and~* previous chemotherapy or abdominal/pelvic radiation therapy.~* After randomization, other exclusion criteria will include a surgical procedure longer than 6 h, inability to extubate the trachea within 4 h after operation, evidence of a new postoperative myocardial infarction, abnormal postoperative mental status or any new neurologic deficit, significant postoperative bleeding (with a hemoglobin level \< 7.5 g/dL), requiring blood transfusion, or a urine output of less than 30 mL/h.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Celecoxib (Type: EXPERIMENTAL): Celecoxib, 200 mg tab
- Placebo (Type: PLACEBO_COMPARATOR): placebo, tab

Based on this trial design, predict the completion outcome and termination type (if applicable).